2seventy bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch 2seventy bio and buy or sell other stocks, ETFs, and their options commission-free!

About TSVT

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. 

CEO
Chip Baird, III, MBA
CEOChip Baird, III, MBA
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2021
Founded2021
Employees
Employees

TSVT Key Statistics

Market cap
262.33M
Market cap262.33M
Price-Earnings ratio
-49.12
Price-Earnings ratio-49.12
Dividend yield
Dividend yield
Average volume
150.58K
Average volume150.58K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.30
52 Week high$5.30
52 Week low
$2.29
52 Week low$2.29

Stock Snapshot

With a market cap of 262.33M, 2seventy bio(TSVT) trades at $5.00. The stock has a price-to-earnings ratio of -49.12.

On 2026-04-14, 2seventy bio(TSVT) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 150.58K.

The stock's 52-week range extends from a low of $2.29 to a high of $5.30.

The stock's 52-week range extends from a low of $2.29 to a high of $5.30.

People also own

Based on the portfolios of people who own TSVT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.